Results 111 to 120 of about 302,501 (282)

Characteristics of deaths due to drug‐related causes among individuals recently released from prison in the United Kingdom, 1997–2025

Addiction, EarlyView.
Abstract Background and aims There has been an extensive literature describing the elevated risk of drug‐related death following an individual's release from prison; however, few previous studies have reported nationally representative samples or provided granular detail as to which individual drugs were deemed implicated in death.
Emmert Roberts, John Strang, Caroline Copeland   +2 more
wiley   +1 more source

Implementation and Evaluation of a Bystander Naloxone Training Course

Western Journal of Emergency Medicine
Introduction: Bystander provision of naloxone is a key modality to reduce opioid overdose-related death. Naloxone training courses are available, but no standardized program exists.
Scott G. Weiner, Scott A. Goldberg, Cheryl Lang, Molly Jarman, Cory J. Miller, Sarah Li, Ewelina W. Stanek, Eric Goralnick   +7 more
doaj   +1 more source

Barriers and facilitators to detoxification from opioid substitution treatment: A mixed‐methods systematic review

Addiction, EarlyView.
Abstract Background and aims Despite the well‐documented benefits of opioid substitution treatment (OST) in treating opioid dependence (OD), many people diagnosed with OD desire to live a drug‐free life. The transition to abstinence involves detoxification: a gradual dose reduction of OST to zero milligrams.
Amy Bagshaw, Suleyman Shah, India Olchefske, Louise M. Paterson, Mike J. Crawford, Anne Lingford‐Hughes   +5 more
wiley   +1 more source

Comparative effectiveness of alternative times to opioid agonist treatment taper initiation on taper completion and all‐cause mortality among people with opioid use disorder: A retrospective population‐based target trial emulation study in British Columbia, Canada, 2010–2020

Addiction, EarlyView.
Abstract Background and aims Opioid use disorder (OUD) treatment guidelines worldwide recommend opioid agonist treatment (OAT) as a long‐term, potentially indefinite treatment for managing OUD. However, many individuals express a strong interest in eventually tapering fully off treatment.
Ruyu Yan, Jeong Eun Min, Megan Kurz, Shaun R. Seaman, Paxton Bach, Sander Greenland, Paul Gustafson, Mohammad Ehsanul Karim, Lawrence McCandless, Robert William Platt, Uwe Siebert, María Eugenia Socías, Hui Xie, Bohdan Nosyk   +13 more
wiley   +1 more source

State marijuana laws and opioid overdose mortality

Injury Epidemiology, 2019
Background The opioid epidemic in the United States is a national public health crisis. In recent years, marijuana legalization has been increasingly adopted by state governments as a policy intervention to control the opioid epidemic under the premise ...
Stanford Chihuri, Guohua Li
doaj   +1 more source

Factors associated with the percentage of individuals who initiate and discontinue naltrexone as a relapse prevention pharmacotherapy in opioid use disorder: A systematic review, meta‐analysis and meta‐regression

Addiction, EarlyView.
Abstract Background and aims Naltrexone is a pharmacotherapeutic option for relapse prevention in opioid use disorder (OUD); however, studies highlight low rates of initiation and high rates of discontinuation as limiting its effectiveness. We aimed to (1) estimate the percentage of individuals with OUD who (having undergone withdrawal and wish to ...
Emmert Roberts, Elizabeth Sanderson, Thomas Santo Jr., Matthew Hickman, Michael Farrell, Louisa Degenhardt   +5 more
wiley   +1 more source

A latent class analysis of clinical complexity: Secondary analysis of the collaboration leading to addiction treatment and recovery from other stresses (CLARO) randomized trial

Addiction, EarlyView.
Abstract Background and aims Individuals with opioid use disorder (OUD) frequently present with co‐occurring mental health conditions such as depression and posttraumatic stress disorder (PTSD), along with other mental health substance use disorders, physical health conditions and social determinants that together comprise ‘clinical complexity ...
Megan S. Schuler, Rebecca Weir, Colleen M. McCullough, Grace M. Hindmarch, Beth Ann Griffin, Kirsten Becker, Lisa S. Meredith, Katherine E. Watkins   +7 more
wiley   +1 more source

Drug and Opioid-Involved Overdose Deaths — United States, 2013–2017

MMWR. Morbidity and mortality weekly report, 2018
The 63,632 drug overdose deaths in the United States in 2016 represented a 21.4% increase from 2015; two thirds of these deaths involved an opioid (1).
Lawrence Scholl, P. Seth, Mbabazi Kariisa, N. Wilson, G. Baldwin   +4 more
semanticscholar   +1 more source

The NOD (Naltrexone for Overdose Prevention) study protocol: a pilot randomized controlled trial of intramuscular naltrexone for opioid overdose prevention among people who use stimulants living with or at risk for HIV

Addiction Science & Clinical Practice
Background Drug-related mortality in the United States continues to transform, marked by a surge in overdose deaths involving both fentanyl and stimulants.
Ayesha Appa, Xochitl Luna Marti, Stefan Baral, Steven Shoptaw, Alexander R. Bazazi, Matthew A. Spinelli, Dave Glidden, Monica Gandhi, Phillip Coffin   +8 more
doaj   +1 more source

Trends in drug overdose deaths among adults 65 years of age and older in Canada (2000–2022)

Drug and Alcohol Dependence Reports
Background: Although young adults and middle-aged adults have borne the brunt of the drug overdose crisis in Canada, older adults are also at an increased risk of harms.
Sameer Imtiaz, Farihah Ali, Nat Kaminski, Cayley Russell, Jürgen Rehm   +4 more
doaj   +1 more source